Does Lapatinib Interact with Midazolam?
CDI records a moderate classification for Lapatinib and Midazolam. The stored summary is: Lapatinib increases midazolam exposure by 45% (oral) and 22% (IV) as a CYP3A4 substrate. Monitor and consider dose reduction. The mechanism involves cyp3a4 inhibition by lapatinib. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
- Stored CDI classification
- Moderate
- Midazolam Class
- Benzodiazepine
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 inhibition by lapatinib
What To Tell Your Doctor or Pharmacist
If you are taking Lapatinib and your doctor is considering prescribing Midazolam (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider